%0 Case Reports
%T Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion.
%A Tello K
%A Hoffmann A
%A Beutel B
%A Greulich T
%A Vogelmeier CF
%A Richter MJ
%A Kuhnert S
%A Böselt T
%A Alter P
%A Holland A
%A Idzko M
%A Buhl R
%A Koczulla AR
%J Respir Med Case Rep
%V 28
%N 0
%D 2019
%M 31485410
暂无%R 10.1016/j.rmcr.2019.100927
%X We report about a case of a compassionate off-label use of the anti-interleukin-5-agent mepolizumab in a ventilated patient with life-threatening asthma attack in eosinophilic asthma. The patient suffered from severe eosinophilic asthma and was transmitted to our hospital with an asthma attack and a life-threatening respiratory state under ventilation. Since high dose steroids had not yielded a sufficient respiratory improvement mepolizumab was administered subcutaneously. After administration of mepolizumab respiratory state and ventilation parameter improved significantly. Two days after administration the patient was weaned could be extubated 8 days later and recovered completely from the asthma attack. The presented clinical case is suggestive of future clinical trials or registry studies to evaluate potential clinical benefits of anti-interleukin-5 treatment in patients with severe exacerbations of eosinophilic asthma.